时间： 2011-9-5 至 2011-9-7
地点：新加坡
主办单位： IMAPAC
官方网址： https://www.giichinese.com.cn/conference/world-drugdelivery11/
会议简介
World Drug Delivery Congress 2011(全球药物投递会议)
2011年9月5 - 7日, 新加坡
英文网站：https://www.imapac.com/index.php?page=world-drug-delivery-congress-2011
中文网站：https://www.giichinese.com.cn/conference/world-drugdelivery11/
World Drug Delivery Congress Asia Pacific是无与伦比的会议。
- 网罗小分子药及生物学制剂的整个送达技术。
- 关注亚洲15个以上国家及地区最创新的医药品企业。
- 国际大型医药品企业、特殊医药品企业、通用医药品企业、以及先驱技术企业、学术机关、其他利益攸关者等药物投递的高阶主管齐聚一堂。
2009年，药物投递市场具有1,010亿美元的市场规模。这一数据据推测至2016年将增长约2倍，达到2,000亿美元的规模。
据调查，医药品产业为支持解决「专利悬崖(patent cliff)」和竞争激烈等课题，越发体会到药物投递革新的重要性。
在此背景下，亚太地区及世界各地多国籍企业、特殊医药品企业、通用医药品企业者在「World Drug Delivery Congress 2011」中齐聚一堂，针对各公司为产品管道打造出更新的价值，灵活运用创新药物投递技术，交换意见与进行讨论。
此次的会议有50名以上的业界高阶主管齐聚一堂，是亚太地区过去未曾有过最高水准的集会。讨论的内容从创新的制剂及开发药物投递策略，到新的收益流动与建构可以持续合作关系之能力，准备内容丰富。
会议理念
2009年，药物投递市场创下了1,010亿美元的市场规模。预计在2016年将成长2倍，达到2,000亿美元的规模。
医药品产业致力于强化药物投递策略，开始获得丰硕的成果。Sandoz公司液体笔芯的产品Omnitrope Pen 5成功，可说是药物投递革新如何有别于医药品销售业绩的佳例。
医药品大公司开始致力于依据「专利的悬崖(patent cliff)」强迫进行跳脱以往框架的思考，许多企业为了延长生命周期，开始采用新的药物投递技术。通用医药品企业在面临先行医药品企业和同业其他公司竞争激烈中，开始体会到在市场产品差异化下药物投递技术所具备的力量。药物投递市场维持高成长率可说是无庸赘言的事。以此成长为主，提供药物投递新的价值与新送达物质成本低效率高的制造法，并促进这些技术的进步等。
为使产业的发展具有更好的前景，医药品企业、药物投递企业、以及全部利益攸关者，须相互合作寻求新的革新，充分发挥交流合作的巨大作用。
World Drug Delivery Congress中，众多国际企业和通用医药品企业的高阶主管可以与药物投递企业和生物技术企业会面，充分了解各公司产品管道药物投递的可能性。
讨论内容包含查明新的收益流动、适合各公司产品线新的革新技术之特定、以及建构策略上合作关系等。医药品产业若能将上述配合起来，就能为世界各地所有患者开发更安全、质高、成本效率高的医药品。
World Drug Delivery Congress 2011
https://www.imapac.com/index.php?page=world-drug-delivery-congress-2011
5-7 September 2011 Singapore
A conference that covers the entire spectrum of drug delivery technologies and uncovers the needs of pharmas in Asia and globally.
World Drug Delivery Congress Asia Pacific is UNIQUE, it
- covers the ENTIRE spectrum of drug delivery technologies for both small molecule and biologic drugs
- features the MOST innovative Pharmas from over 15 Asian countries and regions
- brings together KEY drug delivery decision makers from multinational pharmas, speciality and generic pharmas, as well as technology leaders, academics and other stakeholders
Featuring 30+ top notch speakers from Asia''s leading pharma companies, 2 workshops covering the hottest topics on Nanotechnology & Biologic Formulation and Drug Delivery 101. Limited seats, register now to avoid disappointment!
Register now at https://www.imapac.com/index.php?page=world-drug-delivery-congress-2011
In 2009, the drug delivery market was valued at US$101 billion and is forecast to increase about two-folds to an estimate of US$200 billion by 2016.
A recent research have revealed that the pharmaceutical industry is increasingly recognizing the importance of drug delivery innovations in order to help them address challenges such as the patent cliffs and heightened competition.
Against this backdrop, World Drug Delivery Congress 2011 will bring together multinational, specialty and generic pharmaceutical companies from Asia Pacific and globally to exchange ideas and debate on how to leverage on innovative drug delivery technologies to create more value in their product pipelines.
This is Asia Pacific region''s FIRST and HIGHEST LEVEL gathering that brings together more than 50 key decision makers in the pharmaceutical industry in a never been done before event. Discussions are set to range from the developments of innovative drug formulation and delivery strategies, to the ability to create new revenue streams and sustainable partnerships.
The Concept
In 2009, the drug delivery market was valued at US$101 billion and is forecast to increase about two-folds to an estimate of US$200 billion by 2016.
The pharmaceutical industry is paying increasing attention to drug delivery strategies and they have since started to reap sizable rewards. The success of Omnitrope Pen 5 with liquid cartridge by Sandoz is a perfect example of how drug delivery innovations can make a difference to pharmaceutical sales performance.
Patent cliff is forcing pharma giants to think out of the box, and many has turned to novel drug delivery technologies for life-cycle extension. Facing increasing competitions from the originators and peers, generic pharmas have also started to realize the magical power of drug delivery technologies to create product differentiation in the market.
With both multinational and generic players utilizing drug delivery technologies to gain a similar objective of remaining in business, it is not surprising that the drug delivery market have been experiencing high growths. This is driven mainly by the new value proposition of drug delivery, the cost effective manufacture of new delivery materials as well as advances in these technologies.
In order to move the industry forward, pharmaceutical companies, drug delivery firms and all relevant stakeholders should come together to explore new innovations and exploit existing synergies.
World Drug Delivery Congress is designed for this purpose of allowing top decision makers from multinational and generic pharmaceutical companies to meet drug delivery firms and biotechs and unravel the full potential that drug delivery has on their product pipelines.
Discussions include determining new revenue streams, identifying new and innovative technologies suitable for your product lines and forming strategic partnerships. Together, the drug industry can develop safer, better and more cost effective drugs for all patients worldwide.
The Speakers
Jack Aurora, CSO, Hisun pharma, China
Dr Yuen Kah Hay, Director R&D, Hovid, Malaysia
Deepak Murpani, VP R&D (product development), Genepharm, Greece
Vipan Dhall, Site Head Pharmaceutical development services, Piramal Healthcare, India
Peter Hoffmann, Vice president new technology development, Genzyme Corporation, USA
Ursula Redeker, Head Technical Dev Biologics, F. Hoffman La-Roche, Switzerland
Chandir Ramani, Head Product Development, Pharmaniaga, Malaysia
Motoichi Kurisawa Team Leader and Principal Research Scientist, Institute of Bioengineering and Nanotechnology, Singapore
Keith Horspool, Vice president Pharmaceutics, Boehringer Ingelheim, Germany
David Monteith, Head pharmaceutical emerging markets, Merck &Co., USA
Hsu Chang Shan, President, Innopharmax, Taiwan
Vincent Lee, Professor pharmacy, Chinese University of Hong Kong, Hong Kong
Julie Liu, Head Development and Regulatory Oncology injectables, Sandoz, Austria
Kennie Dee, Vice-President Research and development, United Laboratories, Inc., Philippines
Henry Sun, VP Research, Tianjin Tasly Group, China
Ravi Kiron, Managing Director, Adjuant global advisors LLC, USA
Mangesh Deshpande, Manager Formulations R&D, Dr Reddy Laboratories, India
Nazaneen Pourkavoos. Principal Scientist, protein formulation and drug delivery, Novo Nordisk A/S, Denmark
Dr. Yunlong Tseng, Director of R&D, Taiwan Liposome Company, Taiwan
Dr Li You Xin, Vice president, Head of Group R&D, Luye pharmaceutical, China
Vinod Arora, VP pharma R&D, Ranbaxy, India
Lee Chee Wee, Founder and scientific advisor, Lynk Biotech, Singapore
联系方式
联系人：Hu Shu
E-mail：
电 话：+65 6493 2093
